Przemyslaw Sapieha

Przemyslaw Sapieha obtained his Ph.D. in Neuroscience and Cell Biology from the University of Montreal, and completed postdoctoral research first in Pharmacology at the McGill University then in ophthalmology at Harvard Medical School. Dr Sapieha joined the University of Montreal in 2010 where he is currently Assistant Professor Ophthalmology. Since postdoc, Dr. Sapieha demonstrated interest in the retinopathy, when he worked on the patho-mechanisms of retinopathy of prematurity and the roles of metabolism and lipids in this disease. The centre of his research at Montreal is the causes of vascular diseases particularly diabetic retinopathy and age-related macular degeneration. The Sapieha group invests primarily the neurovascular and neuroimmune signalling in diseases; their progress in diabetic retinopathy (DR) has characterized the effect of Semaphorin 3A in ischemic neural zones of the retina and demonstrated that it is a key vaso-repulsive mediator that prevents reparative angiogenesis in models that serve as proxies for DR. The group is in a constant search into different factors responsible for the retinopathy, for instance, recently they elucidated the mechanisms of NOTCH1 signaling pathway inducing pathological vascular permeability in diabetic retinopathy.

Lab Information

University of Montreal

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Angiogenesis 0 Diabetic Retinopathy 0 Age-related Macular degeneration 0 Neurovascular Signaling 0 Lipid Metabolism 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Hachana S, Fontaine O, Sapieha P, Lesk M, Couture R, Vaucher E. The effects of anti-VEGF and kinin B1receptor blockade on retinal inflammation in laser-induced choroidal neovascularization. Br J Pharmacol. 2020;177(9):1949-1966. doi:10.1111/bph.14962

  2. Fournier P, Viallard C, Dejda A, Sapieha P, Larrivée B, Royal I. The protein tyrosine phosphatase PTPRJ/DEP-1 contributes to the regulation of the Notch-signaling pathway and sprouting angiogenesis. Angiogenesis. 2020;23(2):145-157. doi:10.1007/s10456-019-09683-z

  3. Miloudi K, Oubaha M, Ménard C, et al. NOTCH1 signaling induces pathological vascular permeability in diabetic retinopathy. Proc Natl Acad Sci U S A. 2019;116(10):4538-4547. doi:10.1073/pnas.1814711116

  4. Wilson AM, Mazzaferri J, Bergeron É, et al. In Vivo Laser-Mediated Retinal Ganglion Cell Optoporation Using KV1.1 Conjugated Gold Nanoparticles. Nano Lett. 2018;18(11):6981-6988. doi:10.1021/acs.nanolett.8b02896

  5. Joly S, Dejda A, Rodriguez L, Sapieha P, Pernet V. Nogo-A inhibits vascular regeneration in ischemic retinopathy. Glia. 2018;66(10):2079-2093. doi:10.1002/glia.23462

  6. Wilson AM, Shao Z, Grenier V, et al. Neuropilin-1 expression in adipose tissue macrophages protects against obesity and metabolic syndrome. Sci Immunol. 2018;3(21):eaan4626. doi:10.1126/sciimmunol.aan4626

  7. Pasquin S, Chehboun S, Dejda A, et al. Effect of human very low-density lipoproteins on cardiotrophin-like cytokine factor 1 (CLCF1) activity. Sci Rep. 2018;8(1):3990. Published 2018 Mar 5. doi:10.1038/s41598-018-22400-y


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud